BiotechTube

MK-0524A + ER Niacin + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypercholesteremia

Conditions

Hypercholesteremia, Hyperlipidemia

Trial Timeline

Jul 1, 2006 → Jan 1, 2007

NCT ID
NCT00376584

About MK-0524A + ER Niacin + Placebo

MK-0524A + ER Niacin + Placebo is a phase 3 stage product being developed by Merck for Hypercholesteremia. The current trial status is completed. This product is registered under clinical trial identifier NCT00376584. Target conditions include Hypercholesteremia, Hyperlipidemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00376584Phase 3Completed

Competing Products

5 competing products in Hypercholesteremia

See all competitors
ProductCompanyStageHype Score
atorvastatin, LipitorAstellas PharmaApproved
85
Rosuvastatin + HMG CoA inhibitorShionogiApproved
85
SHR-1209 + PlaceboJiangsu Hengrui MedicinePhase 1
33
Rosuvastatin calciumAstraZenecaPhase 3
77
Rosuvastatin + AtorvastatinAstraZenecaPhase 3
77

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85